Switch to fixed-dose doravirine/ islatravir (100/0.75 mg) once daily in adults with HIV-1 virologically suppressed on bictegravir/ emtricitabine/tenofovir alafenamide: Week 96 results of a phase 3, randomized, double-blind, non-inferiority trial

被引：0
|
作者：
Paredes, R. [1 ,2 ]
Mills, A. M. [3 ]
Rizzardini, G. [4 ]
Ramgopal, M. [5 ]
Osiyemi, O. [6 ]
Bogner, J. R. [7 ]
Hagins, D. [8 ]
Reynes, J. [9 ]
Rockstroh, J. K. [10 ]
Carr, A. [11 ]
Su, F. -H. [12 ]
Klopfer, S. O. [12 ]
Correll, T. [12 ]
Fox, M. C. [12 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[2] IrsiCaixa AIDS Res Inst, Barcelona, Spain
[3] Mens Hlth Fdn, Los Angeles, CA USA
[4] Hosp Luigi Sacco, Milan, Italy
[5] Midway Immunol & Res Ctr, Ft Pierce, FL USA
[6] Triple O Res Inst, W Palm Beach, FL USA
[7] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dept Med 4, Munich, Germany
[8] Chatham Cty Hlth Dept, Savannah, GA USA
[9] Montpellier Univ Hosp, Montpellier, France
[10] Univ Bonn, Dept Med 1, Bonn, Germany
[11] St Vincents Hosp, Sydney, Australia
[12] Merck & Co Inc, Rahway, NJ USA
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：188 / 189
页数：2
相关论文
共 50 条
  • [1] Switch to fixed-dose doravirine (100 mg) with islatravir (0<middle dot>75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
    Mills, Anthony M.
    Rizzardini, Giuliano
    Ramgopal, Moti N.
    Osiyemi, Olayemi O.
    Bogner, Johannes R.
    Hagins, Debbie P.
    Paredes, Roger
    Reynes, Jacques
    Rockstroh, Juergen K.
    Carr, Andrew
    Su, Feng-Hsiu
    Klopfer, Stephanie O.
    Eves, Karen
    Plank, Rebeca M.
    Correll, Todd
    Fox, Michelle C.
    [J]. LANCET HIV, 2024, 11 (06): : e357 - e368
  • [2] Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial
    Molina, J. -M.
    Rizzardini, G.
    Kassim, S.
    Saud, A. Afani
    Calmy, A.
    Oka, S.
    Hinestrosa, F.
    Kumar, P.
    Tebas, P.
    Walmsley, S.
    Grandhi, A.
    Klopfer, S.
    Joseph, S.
    Eves, K.
    Correll, T.
    Fox, M. C.
    Kim, J.
    [J]. HIV MEDICINE, 2023, 24 : 185 - 187
  • [3] Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/ emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: Week 48 results from a randomized, double-blind phase 3 trial
    Post, F. A.
    Di Perri, G.
    Cunningham, D.
    Mussini, C.
    Rockstroh, J. K.
    Correll, T. A.
    McMullan, C. J.
    Karten, M.
    Zhang, Y.
    Squires, K.
    Fox, M. C.
    Pisculli, M.
    [J]. HIV MEDICINE, 2023, 24 : 189 - 191
  • [4] Doravirine/Islatravir (100mg/0.75mg) once daily compared to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as Initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial
    Rockstroh, J. K.
    Paredes, R.
    Cahn, P.
    Molina, J. -M.
    Sokhela, S.
    Hinestrosa, F.
    Kassim, S.
    Ortega, E. Valencia
    Cunningham, D.
    Ghosn, J.
    Bogner, J. R.
    Gatanaga, H.
    Asante-Appiah, E.
    Zang, Y.
    Klopfer, S. O.
    Eves, K.
    Pisculli, M. L.
    Squires, K.
    Correll, T. A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [5] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
    Molina, Jean-Michel
    Ward, Douglas
    Brar, Indira
    Mills, Anthony
    Stellbrink, Hans Juergen
    Lopez-Cortes, Luis
    Ruane, Peter
    Podzamczer, Daniel
    Brinson, Cynthia
    Custodio, Joseph
    Liu, Hui
    Andreatta, Kristen
    Martin, Hal
    Cheng, Andrew
    Quirk, Erin
    [J]. LANCET HIV, 2018, 5 (07): : E357 - E365
  • [6] Switch to fixed-dose doravirine (100 mg) with islatravir (0<middle dot>75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
    Molina, Jean-Michel
    Rizzardini, Giuliano
    Orrell, Catherine
    Afani, Alejandro
    Calmy, Alexandra
    Oka, Shinichi
    Hinestrosa, Federico
    Kumar, Princy
    Tebas, Pablo
    Walmsley, Sharon
    Grandhi, Anjana
    Klopfer, Stephanie
    Gendrano, Isaias
    Eves, Karen
    Correll, Todd A.
    Fox, Michelle C.
    Kim, Jason
    [J]. LANCET HIV, 2024, 11 (06): : e369 - e379
  • [7] Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Stellbrink, Hans-Juergen
    Arribas, Jose R.
    Stephens, Jeffrey L.
    Albrecht, Helmut
    Sax, Paul E.
    Maggiolo, Franco
    Creticos, Catherine
    Martorell, Claudia T.
    Wei, Xuelian
    Acosta, Rima
    Collins, Sean E.
    Brainard, Diana
    Martin, Hal
    [J]. LANCET HIV, 2019, 6 (06): : E364 - E372
  • [8] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial (vol 5, pg e545, 2018)
    Molina, J-M
    Ward, D.
    Brar, I
    [J]. LANCET HIV, 2018, 5 (10): : E545 - E545
  • [9] Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial
    Cassetti, I.
    Walmsley, S.
    Mngqibisa, R.
    Rockstroh, J.
    Paredes, R.
    McDonald, C.
    Nwoke, U.
    Klopfer, S. O.
    Karten, M.
    Eves, K.
    Correll, T. A.
    Squires, K.
    Fox, M. C.
    Pisculli, M. L.
    [J]. HIV MEDICINE, 2023, 24 : 199 - 200
  • [10] Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Wohl, David A.
    Yazdanpanah, Yazdan
    Baumgarten, Axel
    Clarke, Amanda
    Thompson, Melanie A.
    Brinson, Cynthia
    Hagins, Debbie
    Ramgopal, Moti N.
    Antinori, Andrea
    Wei, Xuelian
    Acosta, Rima
    Collins, Sean E.
    Brainard, Diana
    Martin, Hal
    [J]. LANCET HIV, 2019, 6 (06): : E355 - E363
12345